NAFLD and NASH are highly prevalent amongst patients with obesity [9–12] and approximately 50% of people affected by obesity have elevated levels of ALT and co-existing NAFLD [13]. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatohepatitis.